Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of TARS is 87 and suggests 39% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell